242
Acad Dermatol Venereol 1998; 10:12-21.
54.
Tosti A, Misciali C, Bardazzi F, Fanti PA, Varotti C. Telogen effluvium due to
recombinant interferon alpha-2b. Dermatology 1992; 184:124-125.
55.
Zeuzem S, Andreone P, POL S ve ark. Telaprevir for retreatment of HCV infection.
N Engl J Med 2011; 364:2417-2428.
56.
Melia MT, Brau N, Poordad F ve ark. Infections during peginterferon/ribavirin
therapy are associated with the magnitude of decline in absolute lymphocyte
count: results of the IDEAL study. Clin Infect Dis 2014; 58:960-969.
57.
World Health Organization. Drospirenone-containing combined oral
contraceptives: possible increased risk of blood clots. WHO Pharm Newslett.
2011;6:5.
58.
Incivek (Telaprevir) [package insert], Vertex Inc.Cambridge MA. April 2013.
59.
Victrelis (Boceprevir) [package insert], Merck Inc. February 2013.
60.
Simeprevir [package insert]. Janssen-Cilag, SpA, Latina, Italy. Janssen Products, LP,
2013.
61.
Jacobson IM, Dore, GJ, Foster GR, ve ark. Simeprevir (TMC435) with
peginterferon/ribavirin for chronic hCV genotype 1 infection in treatment-naïve
patients: results from QUEST-1, a phase III trial. Presented at the 48th annual
meeting of the European Association for the Study of the Liver, Amsterdam, The
Netherlands, April 24-28, 2013. Abstract 1425.
62.
Manns M, Marcellin P, Poordad F ve ark. Simeprevir (TMC435) with peginterferon/
ribavirin for treatment of chronic HCV genotype 1 infection in treatment-naive
patients: results from QUEST-2, a phase III trial. Presented at the 48th annual
meeting of the European Association for the Study of the Liver, Amsterdam, The
Netherlands, April 24-28, 2013. Abstract 1413.
63.
Williams JA, Ring BJ, Cantrell VE ve ark. Comparative metabolic capabilities of
CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos 2002; 30:883-891.
64.
Sofosbuvir [package insert]. Foster City, CA: Gilead Sciences, Inc, 2013.
65.
Lawitz E, Mangia A, Wyles D ve ark. Sofosbuvir for previously untreated chronic
hepatitis C infection. N Engl J Med 2013; 368:1878-1887.
66.
Kowdley KV, Lawitz E, Crespo I ve ark. Sofosbuvir with pegylated interferon alfa-
2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection
(ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 2013;
381:2100-2107.
67.
FDA Hepatitis Update–Important safety information: Harvoni and Sovaldi. March
21, 2015.
(Accessed on March 30, 2015).
68.
Sulkowski MS, Gardiner DF, Rodriguez-Torres M ve ark. Daclatasvir plus sofosbuvir
for previously treated or untreated chronic HCV infection. N Engl J Med 2014;
370:211-221.
69.
Nelson DR, Cooper JN, Lalezari JP ve ark. All-oral 12-week treatment with
daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection:
ALLY-3 phase III study. Hepatology 2015; 61:1127-1135.
70.
A 4-drug combination (Viekira Pak) for hepatitis C. JAMA 2015; 313:1857-1858.
71.
Zeuzem S, Jacobson IM, Baykal T ve ark. Retreatment of HCV with ABT-450/r-
ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370:1604-1614.
